Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Africa

- PMLiVE

Improved health communications needed with the UK’s South Asian communities

Red Door Communications launches ethnic minority outreach programme

- PMLiVE

Mixed reaction to Novo Nordisk obesity trial

Analyst says Victoza only has a modest ability to reduce weight in people with diabetes

- PMLiVE

FDA investigates pancreas risk of diabetes drugs

Products from Merck & Co, BMS, AZ, Novo Nordisk, Boehringer, Amylin and Takeda all involved

- PMLiVE

Informatics to drive clinical trials in UK

Scotland’s chief scientist says NHS data can support medicines research

Astellas files diabetes drug ipragliflozin in Japan

Its SGLT2 inhibitor could beat AZ-BMS' rival Forxiga to debut in that market

- PMLiVE

GSK submits albiglutide for European approval

If approved the diabetes drug will be launched as Eperzan

- PMLiVE

FDA approves J&J’s Bluetooth blood glucose monitor

Licenses iPhone, iPad and iPod Touch compatible monitoring system

- PMLiVE

Novo’s Lantus rival Tresiba hits European markets

Company says its insulin degludec is a more flexible alternative to Sanofi's product

Sanofi reception

FDA to review Sanofi’s lixisenatide for diabetes

Follows drug's European approval under brand name Lyxumia earlier this month

- PMLiVE

FDA turns down Novo Nordisk’s Tresiba and Ryzodeg

Decision could delay the US launch of the diabetes drugs by two years or more

- PMLiVE

Sanofi receives EU approvals for diabetes and cancer drugs

Zaltrap and Lyxumia granted marketing authorisation by European Commission

- PMLiVE

NICE turns down diabetes and ovarian cancer drugs for NHS use

Disappointment for BMS/AZ’s Forxiga and Roche’s Avastin

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links